Karuna has built its pipeline on the broad therapeutic potential of its lead product candidate, KarXT, an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post Breaker of Chains: Karuna Therapeutics Challenges Antipsychotic Drug Barrier appeared first on GEN – Genetic Engineering and Biotechnology News.
